165 related articles for article (PubMed ID: 35814385)
1. PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.
Galiger C; Dahlhaus M; Vitek MP; Debatin KM; Beltinger C
Front Oncol; 2022; 12():744984. PubMed ID: 35814385
[TBL] [Abstract][Full Text] [Related]
2. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
Agarwal A; MacKenzie RJ; Pippa R; Eide CA; Oddo J; Tyner JW; Sears R; Vitek MP; Odero MD; Christensen DJ; Druker BJ
Clin Cancer Res; 2014 Apr; 20(8):2092-103. PubMed ID: 24436473
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
[TBL] [Abstract][Full Text] [Related]
4. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
Bhardwaj A; Singh S; Srivastava SK; Honkanen RE; Reed E; Singh AP
Mol Cancer Ther; 2011 May; 10(5):720-31. PubMed ID: 21393425
[TBL] [Abstract][Full Text] [Related]
5. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
[TBL] [Abstract][Full Text] [Related]
6. OP449 inhibits breast cancer growth without adverse metabolic effects.
Shlomai G; Zelenko Z; Antoniou IM; Stasinopoulos M; Tobin-Hess A; Vitek MP; LeRoith D; Gallagher EJ
Endocr Relat Cancer; 2017 Oct; 24(10):519-529. PubMed ID: 28830934
[TBL] [Abstract][Full Text] [Related]
7. Mapping the substrate landscape of protein phosphatase 2A catalytic subunit PPP2CA.
Brewer A; Sathe G; Pflug BE; Clarke RG; Macartney TJ; Sapkota GP
iScience; 2024 Mar; 27(3):109302. PubMed ID: 38450154
[TBL] [Abstract][Full Text] [Related]
8. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
9. A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma.
Fujiwara N; Kawasaki H; Yabe R; Christensen DJ; Vitek MP; Mizuno T; Sato K; Ohama T
J Vet Med Sci; 2013; 75(3):349-54. PubMed ID: 23131782
[TBL] [Abstract][Full Text] [Related]
10. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
11. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
[TBL] [Abstract][Full Text] [Related]
12. Intelectin 1 suppresses the growth, invasion and metastasis of neuroblastoma cells through up-regulation of N-myc downstream regulated gene 2.
Li D; Mei H; Pu J; Xiang X; Zhao X; Qu H; Huang K; Zheng L; Tong Q
Mol Cancer; 2015 Feb; 14():47. PubMed ID: 25889839
[TBL] [Abstract][Full Text] [Related]
13. Suppression of protein phosphatase 2 differentially modulates VEGF- and FGF2-induced signaling in ovine fetoplacental artery endothelial cells.
Song Y; Wang K; Chen DB; Magness RR; Zheng J
Placenta; 2009 Oct; 30(10):907-13. PubMed ID: 19692121
[TBL] [Abstract][Full Text] [Related]
14. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
15. The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma.
Amoroso F; Capece M; Rotondo A; Cangelosi D; Ferracin M; Franceschini A; Raffaghello L; Pistoia V; Varesio L; Adinolfi E
Oncogene; 2015 Oct; 34(41):5240-51. PubMed ID: 25619831
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.
Del Grosso F; De Mariano M; Passoni L; Luksch R; Tonini GP; Longo L
BMC Cancer; 2011 Dec; 11():525. PubMed ID: 22192458
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol augments ER stress and the cytotoxic effects of glycolytic inhibition in neuroblastoma by downregulating Akt in a mechanism independent of SIRT1.
Graham RM; Hernandez F; Puerta N; De Angulo G; Webster KA; Vanni S
Exp Mol Med; 2016 Feb; 48(2):e210. PubMed ID: 26891914
[TBL] [Abstract][Full Text] [Related]
18. Dehydroeffusol inhibits viability and epithelial-mesenchymal transition through the Hedgehog and Akt/mTOR signaling pathways in neuroblastoma cells.
He K; Duan G; Li Y
Eur J Pharmacol; 2018 Jun; 829():93-101. PubMed ID: 29665365
[TBL] [Abstract][Full Text] [Related]
19. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
20. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
